Non-Invasive Plasma Treatment for Cervical Infections: Targeting High- and Low-Risk HPV Variants

Launched by UNIVERSITY HOSPITAL TUEBINGEN · Feb 26, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new type of treatment called Non-Invasive Plasma Treatment for women who have been diagnosed with HPV (human papillomavirus) infections, which can sometimes lead to cervical cancer. The trial is taking place at the University Hospital Tübingen and is currently looking for participants. The goal is to see how effective this treatment is for women with both high-risk and low-risk types of HPV.

To be eligible for this trial, women must be at least 18 years old and have confirmed HPV infections through specific tests. They should have a clearly visible area on their cervix where the HPV is present. Women who have certain serious health conditions or signs of advanced disease are not eligible. If you choose to participate, you will receive the new treatment and will be monitored closely throughout the study. This trial aims to provide valuable insights into a promising new option for treating HPV infections, which is important for women's health.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Inclusion criteria for NIPP treatment
• • Age ≥ 18 years
• • mRNA or DNA-based virus detection by smear (also external findings)
• • Clearly visible transformation zone of the cervix and margins of the lesions corresponding to T1/T2
• • Written informed consent to participate in the study
• • Inclusion criteria for control group
• • Age ≥ 18 years
• • Swab-based mRNA or DNA-based virus detection (also external findings)
• • Clearly visible transformation zone of the cervix corresponding to T1/T2
• • Written informed consent to participate in the study
• Exclusion criteria:
• • The following exclusion criteria apply to both groups of patients (NIPP treatment and control group).
• • Transformation zone not fully visible
• • Evidence of invasive disease
• • Serious cardiovascular diseases